AIMMUNE THERAPEUTICS
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
AIMMUNE THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.aimmune.com
Total Employee:
251+
Status:
Active
Contact:
+1 650 614 5220
Total Funding:
540 M USD
Technology used in webpage:
Domain Not Resolving IPv6 COVID-19 DigiCert SSL AWS Global Accelerator Akamai Hosted Visual Studio Akamai Edge Microsoft Authentication Library For JavaScript Contentful
Similar Organizations
Agile Therapeutics
Agile Therapeutics is pharmaceutical company developing contraceptive healthcare products for women.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development.
Cleo
Cleo is a benefits platform that provides personalized guidance for working families.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
Trevena
Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Nestlé Health Science
Nestlé Health Science investment in Post-IPO Equity - Aimmune Therapeutics
Nestlé Health Science
Nestlé Health Science investment in Post-IPO Equity - Aimmune Therapeutics
Nestlé Health Science
Nestlé Health Science investment in Post-IPO Equity - Aimmune Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Aimmune Therapeutics
Aisling Capital
Aisling Capital investment in Series B - Aimmune Therapeutics
Longitude Capital
Longitude Capital investment in Series B - Aimmune Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - Aimmune Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Aimmune Therapeutics
Fidelity
Fidelity investment in Series B - Aimmune Therapeutics
Longitude Capital
Longitude Capital investment in Series A - Aimmune Therapeutics
Official Site Inspections
http://www.aimmune.com Semrush global rank: 4.79 M Semrush visits lastest month: 1.87 K
- Host name: ec2-54-177-178-67.us-west-1.compute.amazonaws.com
- IP address: 54.177.178.67
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Aimmune Therapeutics"
Company overview - Aimmune
Aimmune Therapeutics is a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies. Our Mission We’re on a mission to transform the lives of patients and their families …See details»
Our focus - Aimmune
Focus Areas Allergies. The global prevalence of allergic disease has risen dramatically over the past 50 years, with up to 40% of the world’s population affected by at least one condition, including asthma; rhinitis; anaphylaxis; …See details»
Nestlé completes acquisition of Aimmune Therapeutics
Oct 14, 2020 Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone …See details»
Nestlé completes acquisition of Aimmune Therapeutics
Oct 14, 2020 Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food …See details»
Aimmune Therapeutics - Crunchbase Company Profile & Funding
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food …See details»
Nestlé to acquire Aimmune Therapeutics - Nestlé Health Science
Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements regarding Aimmune’s business may include: the expectation that Aimmune will need additional …See details»
Nestlé to acquire Aimmune Therapeutics - Nestlé Global
Aug 31, 2020 Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment. Aimmune's recently approved therapy Palforzia® would expand …See details»
Nestlé completes acquisition of Aimmune Therapeutics - Nestlé …
Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a …See details»
Press Release - Nestlé Global
Aimmune’s dependence on the success o PALFORZIA Aimmune’s ability to build a commercial field organization and distribution network; the degree of acceptance of PALFORZIA among …See details»
History - Aimmune
Aimmune Therapeutics was founded directly in response to a united call to action by leading stakeholders in food allergy. An advocacy-sponsored research retreat was held in 2011 that …See details»
Culture of integrity | Aimmune
As an organization committed to improving the lives of patients with serious and potentially life-threatening food, gastrointestinal (GI), and metabolic-related diseases, we hold ourselves to …See details»
Nestlé completes acquisition of Aimmune Therapeutics
Oct 14, 2020 "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support …See details»
Nestlé agrees $2.6bn deal for Aimmune Therapeutics - Financial …
Aug 31, 2020 Nestlé’s health arm has agreed to buy the biopharmaceutical company Aimmune Therapeutics in a $2.6bn deal that will see the consumer goods group push further into food …See details»
Nestlé makes newly acquired Aimmune a stand-alone unit, …
Oct 14, 2020 A longtime executive at Eli Lilly, Oxtoby joined Aimmune last year. The Swiss conglomerate owned about a quarter of Aimmune at the beginning of 2020, and in August agreed to buy the rest in a deal that valued the biotech at about $2.6 billion. The new unit will be part of Nestlé Health Science and continue to be known as Aimmune Therapeutics ...See details»
Aimmune Therapeutics to Present Positive Results from Phase 3 …
Nov 10, 2022 Aimmune Therapeutics, part of Nestlé Health Science, is a biopharmaceutical company that aspires to be a global leader in developing innovative medicines to prevent, …See details»
Nestle to buy Aimmune Therapeutics for $2.6 billion
Aug 31, 2020 Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.See details»
Nestlé completes acquisition of Aimmune Therapeutics
Oct 14, 2020 Aimmune's pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally." Aimmune will continue to …See details»
Nestlé Health Science Invests in Aimmune for Food Allergies …
Nov 4, 2016 Aimmune’s first investigational product using CODIT, AR101 for the treatment of peanut allergy, is a characterized, regulated, oral biological drug product containing the protein …See details»
Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up
Sep 1, 2020 Shares of Aimmune skyrocketed 171.6% following the announcement of the above news on Monday. In fact, the stock has inched up 2.2% so far this year compared with the industry’s rise of 1.2%.See details»